40 related articles for article (PubMed ID: 3519886)
21. Cisplatin-based combination chemotherapy with or without doxorubicin in advanced epithelial ovarian cancer: 8-year update of a randomized multicentric clinical trial. The Gruppo Oncologico Nord Ovest (GONO).
Gadducci A; Brunetti I; Bruzzone M; Carnino F; Chiara S; Conte PF; Fioretti P; Foglia G; Ragni N
Eur J Gynaecol Oncol; 1992; 13(1 Suppl):36-9. PubMed ID: 1511712
[TBL] [Abstract][Full Text] [Related]
22. Ten-year follow-up of patients receiving cisplatin, doxorubicin, and cyclophosphamide chemotherapy for advanced epithelial ovarian carcinoma.
Sutton GP; Stehman FB; Einhorn LH; Roth LM; Blessing JA; Ehrlich CE
J Clin Oncol; 1989 Feb; 7(2):223-9. PubMed ID: 2915238
[TBL] [Abstract][Full Text] [Related]
23. Carboplatin, doxorubicin, and cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide: a randomized trial in stage III-IV epithelial ovarian carcinoma.
Conte PF; Bruzzone M; Carnino F; Chiara S; Donadio M; Facchini V; Fioretti P; Foglia G; Gadducci A; Gallo L
J Clin Oncol; 1991 Apr; 9(4):658-63. PubMed ID: 2066762
[TBL] [Abstract][Full Text] [Related]
24. [Clinical study of topotecan and cisplatin as first line chemotherapy in epithelial ovarian cancer].
Meng LH; Kong BH; Zhang YZ; Yang XS; Wang LJ; Su SL; Jiang J; Cui BX; Wang B
Zhonghua Fu Chan Ke Za Zhi; 2007 Oct; 42(10):683-7. PubMed ID: 18241544
[TBL] [Abstract][Full Text] [Related]
25. Chemotherapy of advanced ovarian cancer with 4'-O-tetrahydropyranyl doxorubicin and cisplatin: a randomized phase II trial with an evaluation of circadian timing and dose-intensity.
Lévi F; Benavides M; Chevelle C; Le Saunier F; Bailleul F; Misset JL; Regensberg C; Vannetzel JM; Reinberg A; Mathé G
J Clin Oncol; 1990 Apr; 8(4):705-14. PubMed ID: 2179481
[TBL] [Abstract][Full Text] [Related]
26. Management of malignant ovarian immature teratoma. Role of adriamycin.
Vergote IB; Abeler VM; Kjørstad KE; Tropé C
Cancer; 1990 Sep; 66(5):882-6. PubMed ID: 2201432
[TBL] [Abstract][Full Text] [Related]
27. [Oxaliplatin and ovarian cancer].
Dieras V; Girre V; Guilhaume MN; Laurence V; Mignot L
Bull Cancer; 2006 Feb; 93 Suppl 1():S35-9. PubMed ID: 16483943
[TBL] [Abstract][Full Text] [Related]
28. Recurrent ovarian granulosa cell tumor: role of combination chemotherapy with report of a long-term response to a cyclophosphamide, doxorubicin and cisplatin regimen.
Muntz HG; Goff BA; Fuller AF
Eur J Gynaecol Oncol; 1990; 11(4):263-8. PubMed ID: 2245809
[TBL] [Abstract][Full Text] [Related]
29. Contemporary management of ovarian cancer.
Im DD; McGuire WP; Rosenshein NB
Obstet Gynecol Clin North Am; 2001 Dec; 28(4):759-73. PubMed ID: 11766150
[TBL] [Abstract][Full Text] [Related]
30. The intracavitary administration of cytarabine to patients with nonhematopoietic malignancies: pharmacologic rationale and results of clinical trials.
Markman M
Semin Oncol; 1985 Jun; 12(2 Suppl 3):177-83. PubMed ID: 3892699
[No Abstract] [Full Text] [Related]
31. A randomized trial comparing cisplatin plus cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide in advanced ovarian cancer.
Conte PF; Bruzzone M; Chiara S; Sertoli MR; Daga MG; Rubagotti A; Conio A; Ruvolo M; Rosso R; Santi L
J Clin Oncol; 1986 Jun; 4(6):965-71. PubMed ID: 3519886
[TBL] [Abstract][Full Text] [Related]
32. Chemotherapy in advanced ovarian carcinoma: current standards of care based on randomized trials.
Thigpen T; Vance R; Puneky L; Khansur T
Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S97-107. PubMed ID: 7835816
[TBL] [Abstract][Full Text] [Related]
33. Cisplatin-based chemotherapy of epithelial ovarian cancer.
Homesley HD
J Surg Oncol Suppl; 1989; 1():21-5. PubMed ID: 2669793
[TBL] [Abstract][Full Text] [Related]
34. Twice-daily, split-course abdominopelvic radiation therapy after chemotherapy and positive second-look laparotomy for epithelial ovarian carcinoma.
Eifel PJ; Gershenson DM; Delclos L; Wharton JT; Peters LJ
Int J Radiat Oncol Biol Phys; 1991 Sep; 21(4):1013-8. PubMed ID: 1917596
[TBL] [Abstract][Full Text] [Related]
35. Ovarian carcinoma. A decade of progress.
Piver MS
Cancer; 1984 Dec; 54(11 Suppl):2706-15. PubMed ID: 6388813
[TBL] [Abstract][Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [New Search]
